• Recruiting

NCT04184050: Phase 1/2: Dose Esc. & Dose Exp. of safety, Tolerability & PK of HPN217 in RRMM

Updated: May 26

NCT04184050: Phase 1/2: Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and PK of HPN217 in Patients With R/R MM


HPN217

A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and PK of HPN217 in Patients With R/R MM


Sponsor

Harpoon Therapeutics


Multiple Locations

International Study

 

ClinicalTrials.gov Identifier: NCT04184050


Official Title: A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patients With Relapsed/Refractory Multiple Myeloma


First Posted : December 3, 2019


Click here to see details on ClinicalTrials.gov

 

Drug: HPN217

BCMA/CD3e Tri-specific T-cell Activating Construct HPN217

BCMA/CD3e Tri-specific T-cell Activating Construct HPN217 (Code C171631)

Anti-BCMA/CD3e TriTAC HPN217

BCMA/CD3 Tri-specific T-cell Activating Construct HPN217

BCMA/CD3e Tri-specific T-cell Activating Construct HPN217

BCMA/CD3e TriTAC HPN217

BCMA/CD3e-specific TriTAC HPN217

HPN 217

HPN-217

HPN217

TriTAC HPN217

 

1408 HPN217-3001: A Phase 1/2 Open-Label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN217, a Bcma-Targeting T-Cell Engager, in Patients with Relapsed/Refractory Multiple Myeloma


Program: Oral and Poster Abstracts


Session: 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster I

Hematology Disease Topics & Pathways:

Biological, Adult, Diseases, Therapies, immunotherapy, Study Population, Clinically relevant

Saturday, December 5, 2020, 7:00 AM-3:30 PM

 

Locations

United States, Arizona

United States, California

United States, Colorado

United States, Kansas

United States, New York

United States, Oregon

United States, Washington


Europe

France

Germany

Spain




Posts Archive